[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Deutsches Herzzentrum Muenchen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":251},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,71,92,126,148,172,198,222],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100619427","retrospective-natural-history-study-of-rasopathy-associated-cardiomyopathy-ras-cm-100619427",false,"NCT07344480","Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)","RAS-CM","Inclusion Criteria:\n\n* Molecular genetic diagnosis of a RASopathy (i.e., a pathogenic or likely pathogenic variant in one of the RAS-MAPK pathway genes identified, irrespective of when performed)\n* Imaging diagnosis of myocardial hypertrophy (echocardiography) showing a maximal end-diastolic wall thickness of greater than normal (z-score \\> 2) with or without outflow tract obstruction\n* Admitted to hospital between 01\u002F01\u002F2015 and 06\u002F30\u002F2019 for congestive heart failure\\* or developing progressive congestive heart failure during any hospital stay within first 6 months of life\\*\\*\n\n  * Ross score calculated from medical history and physical examination notes in the absence of any other reason prompting hospital admission (e.g., elective procedure, other organ dysfunction, etc.); \\*\\*: defined by Ross Score greater than 2\n\nExclusion Criteria:\n\n* Receiving mechanistic Target of Rapamycin Inhibitor (mTOR inhibitor) and\u002For Mitogen-Activated Protein Kinase Kinase Inhibitor (MEK inhibitors)\n* Inability to identify or retrospectively calculate the patient´s Ross Score within the first six months of life","ALL",{"count":18,"type":19},100,"ESTIMATED","12 Months","OBSERVATIONAL","RASopathy-associated hypertrophic cardiomyopathy (RAS-CM) is a disease with high morbidity and high mortality if presenting during infancy. Targeted therapies have shown significant activity in preclinical models and case reports. Drugs that target the underlying cause of this disease are now developed in cancer patients. Conducting randomized trials is not possible in severely ill infants with RAS-CM. Existing historical controls from older eras are not sufficient as external controls to support drug development as they lack critical clinical and genetic information to allow comparison with the cohort planned for future clinical trials.\n\nThe purpose of this investigator-initiated retrospective natural history study is to collect clinical information and genetic information in patients with RAS-CM. The first goal is to establish a data set that meets regulatory requirements for the use as external control data in a future clinical trial, composing non-randomized, single-arm, open-label study cohorts. The second goal is to obtain natural history information that supports the selection of secondary exploratory endpoints chosen in a clinical trial.",[24,25,26],"Hypertrophic Cardiomyopathy (HCM)","Heart Failure","RASopathy","RECRUITING","2026-02-16",{"date":30,"type":31},"2026-02-18","ACTUAL",{"date":33,"type":31},"2025-06-17",{"date":35,"type":19},"2026-12-31",{"name":37,"class":38},"Deutsches Herzzentrum Muenchen","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100544458","intracoronary-stenting-and-additional-results-achieved-by-shockwave-coronary-lithotripsy-100544458","NCT06369142","Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy","Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: A Randomized, Multicenter Study About the Additional Benefit of Coronary Lithotripsy","ISAR-WAVE","Inclusion Criteria:\n\n1. age ≥18 years and able to give informed consent\n2. written informed consent to participate in the clinical trial\n3. typical angina pectoris or non-invasive evidence of relevant ischemia under optimal drug therapy\n4. angiographic evidence of coronary artery disease\n5. de novo lesion in a native coronary artery\n6. target vessel diameter 2.5-4 mm\n7. severe calcification of the target lesion (angiographic grade 3)\n\nExclusion Criteria:\n\n1. myocardial infarction \\\u003C1 week\n2. thrombus in the target vessel\n3. life expectancy due to other disease \\\u003C1 year\n4. simultaneous participation in a clinical trial with medical devices or medicinal products that has not yet been completed\n5. pregnancy (current, suspected, planned) or positive pregnancy test","18 Years",{"count":50,"type":19},666,"INTERVENTIONAL",[53],"NA","The clinical trial is intended to evaluate the efficacy, safety and economic benefit of coronary lithotripsy compared to other additional procedures (cutting or super high pressure balloon angioplasty, ablative procedures) in lesion preparation and interventional treatment of severely calcified coronary stenoses.",[56],"Coronary Artery Disease",[56,58,59,60,61],"Calcified lesion","Percutaneous Coronary Intervention","Stent","Intravascular Lithotripsy","2026-01-05",{"date":64,"type":31},"2026-01-06",{"date":66,"type":31},"2024-07-01",{"date":68,"type":19},"2027-07-31",{"name":37,"class":38},22,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":39},"100578690","pacemaker-implantation-following-transcatheter-tricuspid-valve-replacement-100578690","NCT06814574","Pacemaker Implantation Following Transcatheter Tricuspid Valve Replacement","Pacemaker Implantation Following Transcatheter Tricuspid Valve Replacement - Single Center Experience","Inclusion Criteria:\n\n* Transcatheter Tricuspid Valve Replacement\n\nExclusion Criteria:\n\n* no defined exclusion criteria",{"count":79,"type":19},25,"Transcatheter tricuspid valve replacement (TTVR) is associated with a high risk of third-degree atrioventricular block (AVB). However, the optimal pacemaker management following TTVR remains unclear. This study aims to identify an optimal therapeutic approach for pacemaker implantation in patients undergoing TTVR.",[82,83],"AV Block Complete","Tricuspid Regurgitation (TR)","2025-02-06",{"date":86,"type":31},"2025-02-07",{"date":88,"type":31},"2024-01-01",{"date":90,"type":19},"2025-01-31",{"name":37,"class":38},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":51,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":39},"100564245","digital-health-promotion-for-children-with-congenital-heart-disease-and-their-guardians-100564245","NCT06626672","Digital Health Promotion for Children With Congenital Heart Disease and Their Guardians","Digital Lifestyle Intervention to Promote Physical Activity, Nutrition, and Health Literacy in Children With Congenital Heart Disease and Their Guardians","Inclusion Criteria:\n\n* Ages 8-14 years\n* Presence of a congenital heart defect (must be moderate or complex according to ACC criteria)\n* NYHA Class I or II\n* Presence of written informed consent\n\nExclusion Criteria:\n\n* Cognitive impairments that inhibit patients from understanding the tasks\n* No sports clearance by paediatric cardiologists","8 Years","14 Years",{"count":102,"type":19},60,[53],"Congenital heart disease (CHD) affects approximately 1% of live births, and children with CHD often fail to meet WHO physical activity guidelines. Digital interventions to promote physical activity in CHD patients are limited. This study will develop and test a 12-week digital lifestyle intervention for children (ages 8-13) and their guardians, using a Garmin Vivofit Jr. 2 wearable to continuously monitor physical activity (PA). We will assess its impact on children's moderate to vigorous intensity physical activity (MVPA), daily activity (steps per day), quality of life, nutrition, and health literacy, as well as the quality of life and health literacy of their parents.",[106,107],"Congenital Heart Disease","Pediatric ALL",[106,109,110,111,112,113,114,115,116,117],"Congenital Heart Defect","Child","Physical Activity","Exercise","MVPA","Digital Health","Telemedicine","Health literacy","Quality Of Life","2025-01-27",{"date":120,"type":31},"2025-01-29",{"date":122,"type":31},"2024-10-01",{"date":124,"type":19},"2026-02",{"name":37,"class":38},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":51,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100481120","intracoronary-stenting-and-restenosis---randomized-trial-of-drug-eluting-stent-implantation-or-drug-coated-balloon-angioplasty-according-to-neointima-morphology-in-drug-eluting-stent-restenosis-5-100481120","NCT05544864","Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5","ISAR-DESIRE5","Inclusion Criteria:\n\n1. Patients with ischemic symptoms and\u002For evidence of myocardial ischemia\n2. Presence of ≥ 50% restenosis after prior implantation of drug-eluting stents in native coronary vessels.\n3. Availability of an OCT-pullback of the target lesion\n4. Written informed consent by the patient for participation in the study.\n5. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Cardiogenic shock\n2. Acute ST-elevation myocardial infarction within 48 hours from symptom onset.\n3. Target lesion located in left main trunk or bypass graft.\n4. Additional coronary intervention planned within 30 days of the procedure.\n5. Non-successful treatment of other lesion(s) during the same procedure\n6. Severe renal insufficiency (glomerular filtration rate ≤ 30 ml\u002Fmin)\n7. Contraindications to any components of the investigational devices or dual antiplatelet therapy\n8. Pregnancy (present, suspected or planned) or positive pregnancy test.\n9. Previous enrollment in this trial or participation in any other study at the time of enrollment.\n10. Malignancies or other comorbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance.\n11. Patient's inability to fully comply with the study protocol",{"count":134,"type":19},376,[53],"The hypothesis of the study is, that there is a significant interaction in treatment effect between the OCT pattern of neointima (heterogeneous or homogeneous) and the type of percutaneous coronary intervention (drug-eluting stent or drug-coated balloon) in patients with in-stent restenosis.",[56,138],"Restenoses, Coronary","2025-01-03",{"date":141,"type":31},"2025-01-06",{"date":143,"type":31},"2022-09-28",{"date":145,"type":19},"2026-09",{"name":37,"class":38},5,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":39},"100162684","anesthesia-for-catheter-aortic-valve-implantation-registry-100162684","NCT01390675","Anesthesia for Catheter Aortic Valve ImplantATIOn Registry","AVIATOR","Inclusion Criteria:\n\n\\- Patients undergoing transcatheter aortic valve implantation (TAVI)\n\nExclusion Criteria:\n\n\\- Refusal by patient",{"count":156,"type":19},10000,"In modern cardiac surgery and cardiology Transcatheter Aortic Valve Implantation (TAVI) is an emerging procedure for high-risk patients that are assumed to be otherwise inoperable. The investigators want to evaluate the specific intraoperative anesthesiologic characteristics cardiac anesthesiologists have to face during these procedures.",[25,159,160,161,162,163],"Excessive Amount of Blood \u002F Fluid Transfusion","Intraoperative Cardiac Arrest During Cardiac Surgery","Critical Incident","Anesthesia","Failed Conscious Sedation During Procedure","2024-08-05",{"date":166,"type":31},"2024-08-07",{"date":168,"type":4},"2011-06",{"date":170,"type":19},"2027-12",{"name":37,"class":38},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":51,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":39},"100520772","lambre-versus-amplatzer-amulet-left-atrial-appendage-occluder-for-stroke-prophylaxis-100520772","NCT06060912","LAmbre Versus AMPLATZER Amulet Left AtrIal Appendage Occluder for StRoke ProphylaxIs","LAmbre Versus AMPLATZER Amulet Left AtrIal Appendage Occluder for StRoke ProphylaxIs: The Randomized AMPIRI Trial","AMPIRI","Inclusion Criteria:\n\n* Age ≥ 18 years and able to give consent\n* Documented paroxysmal, persistent or permanent non-valvular atrial fibrillation\u002F atrial flutter (AF) at high risk of stroke or systemic embolism defined by CHA2DS2-VASc score ≥ 2 (male) or ≥ 3 (female)\n* Patient not eligible for long-term oral anticoagulation therapy\n* Deemed suitable for percutaneous LAAO\n* Able to comply with the required medication regimen after LAAO device implantation\n* Written informed consent\n* LAA anatomy can accommodate either a LAmbre or AMPLATZER Amulet LAAO device, as per manufacturer's instruction for use (IFU) (the anatomy and sizing must be appropriate for both devices in order to be enrolled in the trial)\n* For women of childbearing potential, negative pregnancy test and agree to use reliable method of birth control during the study\n\nExclusion Criteria:\n\n1. Indication for long-term oral anticoagulation therapy for a condition other than AF (i. e. pulmonary embolism, mechanical heart valve)\n2. LAA is obliterated or surgically ligated\n3. Known allergy or hypersensitivity to any component of the LAAO devices or components of the required medication regimen\n4. Prior atrial septal defect (ASD) repair or implantation of ASD closure device\n5. Active endocarditis or other infection producing bacteremia\n6. Significant symptomatic carotid artery disease\n7. Participation in a concurrent clinical trial, which may confound the results of this trial\n8. Patient cannot adhere to or complete the trial protocol for any reason\n\n   Or any of the following echocardiographic exclusion criteria:\n9. Intracardiac thrombus\n10. Intracardiac tumor\n11. Existing, clinically relevant circumferential pericardial effusion\n12. Significant mitral valve stenosis","100 Years",{"count":182,"type":19},226,[53],"The objective of this trial is to compare two different commercially available left atrial appendage occlusion (LAAO) devices in patients with non-valvular Atrial fibrillation\u002F atrial flutter (AF) at increased risk for stroke with regard to safety and efficacy.\n\nThe investigators hypothesize that LAAO using the LAmbre occlusion device (Lifetech Scientific, Shenzhen, China) is non-inferior to LAAO using the AMPLATZER Amulet occlusion device (Abbott Medical, Chicago, ILL, USA) with regards to the primary endpoint, which is peri-device leak (PDL) size 3 months after LAAO, as assessed with transesophageal echocardiography (TOE) in patients with non-valvular AF.",[186],"Left Atrial Appendage Occlusion",[186,188,189],"Non-pharmacological anticoagulation therapy","Stroke prophylaxis","2024-01-07",{"date":192,"type":31},"2024-01-09",{"date":194,"type":31},"2023-12-05",{"date":196,"type":19},"2027-10-15",{"name":37,"class":38},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":205,"enrollmentInfo":206,"targetDuration":208,"studyType":21,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":39},"100406809","the-prospecive-observational-munich-interventional-mitral-valve-registry-100406809","NCT04577248","The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry","OBSERV-MITRA","Inclusion Criteria:\n\n* Age above 18 years and consentable\n* Mitral Valve Regurgitation, Mitral Valve Stenosis, Tricuspid Valve Regurgitation, Tricuspid Stenosis\n* Transcatheter mitral or tricuspid valve therapy considered best option by heart-team decision\n* Written informed consent\n\nExclusion Criteria:\n\n* Patient's inability to fully cooperate with the protocol","110 Years",{"count":207,"type":19},5000,"5 Years","Prospective, single-center observational registry including all consecutive patients treated with transcatheter mitral or tricuspid valve therapy at the Deutsches Herzzentrum München, Germany.",[211,212,213],"Mitral Valve Regurgitation","Mitral Valve Stenosis","Tricuspid Valve Regurgitation","2020-10-06",{"date":216,"type":31},"2020-10-08",{"date":218,"type":31},"2020-09-15",{"date":220,"type":19},"2031-01-01",{"name":37,"class":38},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":51,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":39},"100331853","trirec---trileaflet-reconstruction-of-the-aortic-valve-with-autologous-pericardium-100331853","NCT03600662","TriRec - Trileaflet Reconstruction of the Aortic Valve With Autologous Pericardium","TriRec - Trileaflet Reconstruction of the Aortic Valve","TriRec","Inclusion Criteria:\n\n* Age \\>= 50 years\n* Documented symptomatic moderate or greater aortic stenosis or severe insufficiency\n* Aortic annulus \\> 19 mm\n* Written informed consent of the patient.\n\nExclusion Criteria:\n\n* Concomitant intervention of the aortic root\n* Concomitant intervention of the aortic arch\n* Concomitant valve surgery\n* Emergency surgery for any reason\n* Neurological events (i.e. stroke, TIA) within 6 months preoperatively\n* Coagulation disorders (including thrombocytopenia \\\u003C 100.000\u002Fml)\n* Porcelain aorta\n* Active endocarditis or other active systemic infections\n* Participating in another trial that may influence the outcome of this trial\n* Pregnancy\n* Dual antiplatelet therapy\n* Previous cardiac surgery (excluding percutaneous procedures)","50 Years",{"count":232,"type":19},128,[53],"Reconstruction of the aortic valve using the tri-leaflet repair technique is non-inferior with regard to effective orifice area (EOA) to surgical aortic valve replacement (SAVR) with a biological prosthesis (St. Jude Trifecta GT) as gold- standard.",[236],"Alternative Surgical Treatment for Aortic Valve Disease",[238,239,240,241,242],"aortic stenosis","aortic regurgitation","Trileaflet reconstruction of the aortic valve","Biological aortic valve prosthesis","Effective orifice area","2018-07-16",{"date":245,"type":31},"2018-07-26",{"date":247,"type":31},"2018-01-18",{"date":249,"type":19},"2030-01",{"name":37,"class":38},""]